Nephrol Dial Transplant (2002) 17: 824-828
© 2002 European Renal Association-European Dialysis and Transplant Association
Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function
1 Department of Radiology and 2 Department of Nephrology, Medizinische Klinik – Innenstadt, Ludwig-Maximilians-University, Munich, Germany
Background. The study was designed to investigate the safety and feasibility of gadopentetate dimeglumine, a gadolinium-based contrast medium, as an alternative angiographic contrast agent in patients with impaired renal function and high risk for iodinated contrast-induced nephropathy.
Methods. Gadopentetate dimeglumine was used as the radiographic contrast agent in 32 diagnostic or interventional angiographic procedures in 29 patients (59% diabetics) with severe renal insufficiency (average serum creatinine of 3.6±1.4 mg/dl). The average dose of gadopentetate dimeglumine was 0.34±0.06 mmol/kg body weight. Gadopentetate dimeglumine was used either alone (n=20) or in conjunction with carbon dioxide (n=12).
Results. Thirty-two angiographic procedures (24 diagnostic angiographies and 8 interventional procedures) were performed in 29 patients. For diagnostic purposes, eleven selective renal arteriographies, six angiographies of the iliac arteries and lower extremities, and seven venous angiographies of the upper extremity and central veins were performed. Interventional procedures consisted of two percutaneous transluminal renal angioplasties with stenting, four percutaneous peripheral vascular interventions, and two balloon angioplasties of a dialysis fistula. None of the patients, except one, had evidence of post-procedure contrast material-induced renal failure (increase in serum creatinine >0.5 mg/dl within 72 h) or other complications. This patient had a clinically important increase in serum creatinine level after percutaneous transluminal renal angioplasty and stenting, probably due to cholesterol embolism. Gadopentetate dimeglumine had sufficient radiographic density to allow adequate diagnostic visualization with digital subtraction equipment in all cases.
Conclusions. Gadopentetate dimeglumine is an alternative and safe radiographic contrast agent for angiography and interventional procedures in patients with severe pre-existing renal impairment. In this population with high risk for contrast-induced acute renal failure, it is obviously less nephrotoxic than iodinated contrast media.
Keywords: angiography; contrast induced nephropathy; gadolinium; gadopentetate dimeglumine; renal artery stenosis
Correspondence and offprint requests to: Johannes Rieger, MD, Institut für Klinische Radiologie – Standort Innenstadt, Poliklinik, Pettenkoferstrasse 8a, D-80336 München. Email: jrieger{at}radin.med.uni-muenchen.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Habibi, M. S. Krishnam, D. G. Lohan, F. Barkhordarian, M. Jalili, R. S. Saleh, S. G. Ruehm, and J. P. Finn High-Spatial-Resolution Lower Extremity MR Angiography at 3.0 T: Contrast Agent Dose Comparison Study Radiology, August 1, 2008; 248(2): 680 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Kane, A. W. Stanson, D. Kalnicka, D. W. Rosenthal, C. U. Lee, S. C. Textor, and V. D. Garovic Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1233 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sayin, S. Turhan, O. Akyurek, and M. Kilickap Gadolinium:Nonionic Contrast Media (1:1) Coronary Angiography in Patients With Impaired Renal Function Angiology, November 1, 2007; 58(5): 561 - 564. [Abstract] [PDF]
|
|
|
|
 |
|
 B. M. Elicker, Y. S. Cypel, and J. C. Weinreb IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. Am. J. Roentgenol., June 1, 2006; 186(6): 1651 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ergun, K. Keven, I. Uruc, Y. Ekmekci, B. Canbakan, I. Erden, and O. Karatan The safety of gadolinium in patients with stage 3 and 4 renal failure Nephrol. Dial. Transplant., March 1, 2006; 21(3): 697 - 700. [Abstract] [Full Text] [PDF]
|
|